Importance of Shared Decision-Making and Tailored Treatment in Psoriasis Care

EP: 1.Personalizing Psoriasis Treatment and Site-of-Care Decisions

EP: 2.Managing Psoriasis in a 72-Year-Old Woman through In-Office Biologic Administration

EP: 3.Incorporating Patient Lifestyle into Treatment Decisions in a 64-Year-Old Man with Late-Onset Psoriasis

EP: 4.Involving the Patient in Their Psoriasis Treatment With a 42-Year-Old Woman With a Busy Lifestyle

Now Viewing

EP: 5.Importance of Shared Decision-Making and Tailored Treatment in Psoriasis Care

Dr. Noor concludes by emphasizing the critical importance of ongoing patient monitoring and communication throughout biologic treatment. Regular follow-up visits, particularly with in-office injection protocols, allow dermatologists to assess treatment effectiveness, monitor for adverse effects, and maintain strong patient-provider relationships. He stresses asking patients about itch levels, quality-of-life impacts, and how psoriasis affects daily activities including clothing choices, social interactions, and travel plans.

Treatment modifications require careful timing and patient communication, typically occurring after 3 to 4 months of therapy based on patient trajectory and improvement levels. Noor emphasizes that treatment success definitions may differ between patients and providers, making open communication essential for achieving optimal outcomes. The collaborative approach ensures patients feel engaged in their treatment decisions and are more likely to adhere to prescribed regimens.

Patient-centered care and shared decision-making form the foundation of successful psoriasis management. Noor highlights that matching therapy to the patient, not just the disease, is crucial for treatment success. Factors including age, medication access, lifestyle considerations, mental health status, and support systems influence treatment outcomes. The importance of ongoing provider-patient collaboration cannot be understated, as sending a prescription without follow-up support significantly reduces the likelihood of treatment success. Tildrakizumab’s safety profile, including absence of boxed warnings and minimal contraindications for patients with cardiovascular or metabolic comorbidities, makes it suitable for diverse patient populations requiring personalized psoriasis care.